These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 25350288)

  • 1. A single intramuscular vaccination of mice with the HSV-1 VC2 virus with mutations in the glycoprotein K and the membrane protein UL20 confers full protection against lethal intravaginal challenge with virulent HSV-1 and HSV-2 strains.
    Stanfield BA; Stahl J; Chouljenko VN; Subramanian R; Charles AS; Saied AA; Walker JD; Kousoulas KG
    PLoS One; 2014; 9(10):e109890. PubMed ID: 25350288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intramuscular vaccination of mice with the human herpes simplex virus type-1(HSV-1) VC2 vaccine, but not its parental strain HSV-1(F) confers full protection against lethal ocular HSV-1 (McKrae) pathogenesis.
    Naidu SK; Nabi R; Cheemarla NR; Stanfield BA; Rider PJ; Jambunathan N; Chouljenko VN; Carter R; Del Piero F; Langohr I; Kousoulas KG
    PLoS One; 2020; 15(2):e0228252. PubMed ID: 32027675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single dose of glycoprotein K (gK)-deleted HSV-1 live-attenuated virus protects mice against lethal vaginal challenge with HSV-1 and HSV-2 and induces lasting T cell memory immune responses.
    Iyer AV; Pahar B; Chouljenko VN; Walker JD; Stanfield B; Kousoulas KG
    Virol J; 2013 Oct; 10():317. PubMed ID: 24165088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination of rhesus macaques with the live-attenuated HSV-1 vaccine VC2 stimulates the proliferation of mucosal T cells and germinal center responses resulting in sustained production of highly neutralizing antibodies.
    Stanfield BA; Pahar B; Chouljenko VN; Veazey R; Kousoulas KG
    Vaccine; 2017 Jan; 35(4):536-543. PubMed ID: 28017425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intramuscular Immunization of Mice with the Live-Attenuated Herpes Simplex Virus 1 Vaccine Strain VC2 Expressing Equine Herpesvirus 1 (EHV-1) Glycoprotein D Generates Anti-EHV-1 Immune Responses in Mice.
    Liu SA; Stanfield BA; Chouljenko VN; Naidu S; Langohr I; Del Piero F; Ferracone J; Roy AA; Kousoulas KG
    J Virol; 2017 Jun; 91(12):. PubMed ID: 28404844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intramuscular vaccination of guinea pigs with the live-attenuated human herpes simplex vaccine VC2 stimulates a transcriptional profile of vaginal Th17 and regulatory Tr1 responses.
    Stanfield BA; Rider PJF; Caskey J; Del Piero F; Kousoulas KG
    Vaccine; 2018 May; 36(20):2842-2849. PubMed ID: 29655629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross protective efficacy of the Non-Neurotropic live attenuated herpes simplex virus type 1 vaccine VC-2 is enhanced by intradermal vaccination and deletion of glycoprotein G.
    Stanfield BA; Bravo FJ; Dixon DA; Chouljenko VN; Kousoulas KG; Bernstein DI
    Vaccine; 2022 Oct; 40(42):6093-6099. PubMed ID: 36114130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intramuscular Vaccination With the HSV-1(VC2) Live-Attenuated Vaccine Strain Confers Protection Against Viral Ocular Immunopathogenesis Associated With γδT Cell Intracorneal Infiltration.
    Nabi R; Lewin AC; Collantes TM; Chouljenko VN; Kousoulas KG
    Front Immunol; 2021; 12():789454. PubMed ID: 34868077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Duration of protection from live attenuated vs. sub unit HSV-2 vaccines in the guinea pig model of genital herpes: Reassessing efficacy using endpoints from clinical trials.
    Bernstein DI; Cardin RD; Pullum DA; Bravo FJ; Kousoulas KG; Dixon DA
    PLoS One; 2019; 14(3):e0213401. PubMed ID: 30917165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The HSV-1 live attenuated VC2 vaccine provides protection against HSV-2 genital infection in the guinea pig model of genital herpes.
    Bernstein DI; Pullum DA; Cardin RD; Bravo FJ; Dixon DA; Kousoulas KG
    Vaccine; 2019 Jan; 37(1):61-68. PubMed ID: 30471955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective immunity against lethal HSV-1 challenge in mice by nucleic acid-based immunisation with herpes simplex virus type-1 genes specifying glycoproteins gB and gD.
    Baghian A; Chouljenko VN; D'Auvergne O; Newman MJ; Baghian S; Kousoulas KG
    J Med Microbiol; 2002 Apr; 51(4):350-357. PubMed ID: 11926742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A herpes simplex virus 1 (McKrae) mutant lacking the glycoprotein K gene is unable to infect via neuronal axons and egress from neuronal cell bodies.
    David AT; Saied A; Charles A; Subramanian R; Chouljenko VN; Kousoulas KG
    mBio; 2012; 3(4):e00144-12. PubMed ID: 22829677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A lentiviral vector-based, herpes simplex virus 1 (HSV-1) glycoprotein B vaccine affords cross-protection against HSV-1 and HSV-2 genital infections.
    Chiuppesi F; Vannucci L; De Luca A; Lai M; Matteoli B; Freer G; Manservigi R; Ceccherini-Nelli L; Maggi F; Bendinelli M; Pistello M
    J Virol; 2012 Jun; 86(12):6563-74. PubMed ID: 22491465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of baculovirus-expressed herpes simplex virus type 1 glycoprotein K.
    Ghiasi H; Slanina S; Nesburn AB; Wechsler SL
    J Virol; 1994 Apr; 68(4):2347-54. PubMed ID: 8139020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CCL19 and CCL28 Assist Herpes Simplex Virus 2 Glycoprotein D To Induce Protective Systemic Immunity against Genital Viral Challenge.
    Yan Y; Hu K; Fu M; Deng X; Luo S; Tong L; Guan X; He S; Li C; Jin W; Du T; Zheng Z; Zhang M; Liu Y; Hu Q
    mSphere; 2021 Apr; 6(2):. PubMed ID: 33910988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection.
    Da Costa XJ; Morrison LA; Knipe DM
    Virology; 2001 Sep; 288(2):256-63. PubMed ID: 11601897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inactivation of the UL37 Deamidase Enhances Virus Replication and Spread of the HSV-1(VC2) Oncolytic Vaccine Strain and Secretion of GM-CSF.
    Clark CM; Jambunathan N; Collantes TMA; Kousoulas KG
    Viruses; 2023 Jan; 15(2):. PubMed ID: 36851581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HF10, an attenuated herpes simplex virus (HSV) type 1 clone, lacks neuroinvasiveness and protects mice against lethal challenge with HSV types 1 and 2.
    Mori I; Liu B; Goshima F; Ito H; Koide N; Yoshida T; Yokochi T; Kimura Y; Nishiyama Y
    Microbes Infect; 2005 Dec; 7(15):1492-500. PubMed ID: 16054416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attenuated Herpes Simplex Virus 1 (HSV-1) Expressing a Mutant Form of ICP6 Stimulates a Strong Immune Response That Protects Mice against HSV-1-Induced Corneal Disease.
    Davido DJ; Tu EM; Wang H; Korom M; Gazquez Casals A; Reddy PJ; Mostafa HH; Combs B; Haenchen SD; Morrison LA
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29950407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Live attenuated herpes simplex virus 2 glycoprotein E deletion mutant as a vaccine candidate defective in neuronal spread.
    Awasthi S; Zumbrun EE; Si H; Wang F; Shaw CE; Cai M; Lubinski JM; Barrett SM; Balliet JW; Flynn JA; Casimiro DR; Bryan JT; Friedman HM
    J Virol; 2012 Apr; 86(8):4586-98. PubMed ID: 22318147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.